Immunological analyses from the FORTE trial that compared 20 versus 40 mg dose of glatiramer acetate in multiple sclerosis

被引：0
|
作者：
Yong, V. W.
Verhaeghe, B.
Silva, C.
Myles, M. L.
Metz, L.
机构：
[1] Hotchkiss Brain Inst, Calgary, AB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S239 / S239
页数：1
相关论文
共 50 条
  • [1] Immunological Responses to Different Doses of Glatiramer Acetate in MS: Analyses from the FORTE Trial
    Yong, Wee V.
    Verhaeghe, Brooke
    Silva, Claudia
    Myles, Mary Lou
    Metz, Luanne M.
    NEUROLOGY, 2009, 72 (11) : A39 - A39
  • [2] Comparing the effect of glatiramer acetate 20 mg vs glatiramer acetate 40 mg on retinal structures in patients with relapsing remitting multiple sclerosis
    Gilroy, M.
    Darling, R.
    Lichtman-Mikol, S.
    Razmjou, S.
    Probst-Simmons, E.
    Santiago-Martinez, C.
    Bernitsas, E.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 647 - 648
  • [3] ADHERENCE TO GLATIRAMER ACETATE 40 MG VERSUS ORAL DISEASE -MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS
    Halpern, R.
    Wolbeck, R.
    Blauer-Peterson, C.
    Wu, Y.
    Gandhi, S. K.
    VALUE IN HEALTH, 2015, 18 (07) : A766 - A766
  • [4] Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review
    Kate McKeage
    CNS Drugs, 2015, 29 : 425 - 432
  • [5] Effect of switching glatiramer acetate formulation from 20 mg daily to 40 mg three times weekly on immune function in multiple sclerosis
    Ito, Kouichi
    Ito, Naoko
    Yadav, Sudhir K.
    Suresh, Shradha
    Lin, Yong
    Dhib-Jalbut, Suhayl
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (03)
  • [6] Adherence to glatiramer acetate 40mg versus oral disease-modifying therapies for multiple sclerosis
    Halpern, R.
    Wolbeck, R.
    Blauer-Peterson, C.
    Wu, Y.
    Gandhi, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 685 - 685
  • [7] Medication Use Patterns of Glatiramer Acetate 40 mg/mL in Patients with Multiple Sclerosis
    Irwin, Debra
    Wu, Ying
    Cappell, Katherine A.
    Davis, Brian M.
    Grinspan, Augusto
    Gandhi, Sanjay K.
    ANNALS OF NEUROLOGY, 2016, 80 : S127 - S127
  • [8] Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review
    McKeage, Kate
    CNS DRUGS, 2015, 29 (05) : 425 - 432
  • [9] Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study
    Zivadinov, Robert
    Bergsland, Niels
    Hagemeier, Jesper
    Tavazzi, Eleonora
    Ramasamy, Deepa P.
    Durfee, Jackie
    Cherneva, Mariya
    Carl, Ellen
    Carl, Jillian
    Kolb, Channa
    Hojnacki, David
    Weinstock-Guttman, Bianca
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2018, 387 : 152 - 156
  • [10] Statistical comparison of adverse events for glatiramer acetate 20mg vs 40mg for the treatment of relapsing-remitting multiple sclerosis
    Zagmutt, F. J.
    Wu, Y.
    Grinspan, A.
    Kolodny, S.
    Gandhi, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 599 - 599
12345